When I first learned about StemEnhance I went looking for research, because let’s face it, when we’re asking the question ‘does StemEnhance really work?‘, being able to read some scientific studies that back up the testimonials of current StemEnhance users helps us to make a decision about whether we try it ourselves.
So this page contains links to research and studies on StemEnhance, plus additional studies or articles about stem cell nutrition that might be of interest. I’ve also quoted from the conclusions on most of the studies for those who don’t have time – or the tenacity – to read the entire novel… 😉
StemEnhance & Muscle Injury
? Mobilization of bone marrow stem cells with StemEnhance® improves muscle regeneration in cardiotoxin-induced muscle injury.
Bone marrow-derived stem cells have the ability to migrate to sites of tissue damage and participate in tissue regeneration. The number of circulating stem cells has been shown to be a key parameter in this process. Therefore, stimulating the mobilization of bone marrow stem cells may accelerate tissue regeneration in various animal models of injury. In this study we investigated the effect of the bone marrow stem cells mobilizer StemEnhance (SE), a water-soluble extract of the cyanophyta Aphanizomenon flos-aquae(AFA), on hematopoietic recovery after myeloablation as well as recovery from cardiotoxin-induced injury of the anterior tibialis muscle in mice. Control and SE-treated female mice were irradiated, and then transplanted with GFP+ bone marrow stem cells and allowed to recover. Immediately after transplant, animals were gavaged daily with 300 mg/kg of SE in PBS or a PBS control. After hematopoietic recovery (23 days), mice were injected with cardiotoxin in the anterior tibialis muscle. Five weeks later, the anterior tibialis muscles were analyzed for incorporation of GFP+ bone marrow-derived cells using fluorescence imaging. SE significantly enhanced recovery from cardiotoxin-injury. However, StemEnhance did not affect the growth of the animal and did not affect hematopoietic recovery after myeloablation, when compared to control. This study suggests that inducing mobilization of stem cells from the bone marrow is a strategy for muscle regeneration.
? Subchronic toxicity (90 days) of StemEnhance™ in Wistar rats
Treatment-related morphological abnormalities were not found in any organs/tissues examined. These findings confirm that high-dose subchronic exposure to StemEnhance does not lead to toxicity. The dose of StemEnhance tested in the rat was ∼7 times higher than the maximum label recommended daily dose for human consumption. Therefore, it would appear that no toxicological hazard is likely due to the use of StemEnhance at label doses.
StemEnhance Does Not Promote Tumor Growth
? The Stem Cell Mobilizer StemEnhance® Does Not Promote Tumor Growth in an Orthotopic Model of Human Breast Cancer.
Bone marrow-derived stem cells (BMDSC) have been implicated in tumor formation, though it is not clear whether they contribute to tumor growth. A novel mobilizer of BMDSC (StemEnhance®; SE) was used to investigate whether its daily administration promotes tumor growth. Forty mice were surgically transplanted with human MDA-MB-435-GFP breast cancer into the mammary fat pad of nude mice. The mice were gavaged for six weeks with 300 mg/kg of SE. Tumor growth was monitored using live whole-body fluorescence imaging. At the end of the study, tumors were excised and weighed. At the start of the feeding trial, tumor areas for both control and experimental group were statistically identical. Tumor growth rate was slower in the SE group (p=0.014) when compared to the control group. After 6 weeks, tumor areas were 40% larger in the control p<0.01) and mean tumor weight was 35% smaller in the SE-treated group (0.44 g vs. 0.68 g; p=0.031). Feeding of SE did not promote tumor growth but rather reduced the growth of human MDA-MB-435 breast cancer.